Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

0.8520
-0.0980-10.32%
Post-market: 0.86680.0148+1.74%19:44 EDT
Volume:5.90M
Turnover:5.10M
Market Cap:168.57M
PE:-3.08
High:0.9332
Open:0.9300
Low:0.8191
Close:0.9500
Loading ...

Esperion Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
18 Apr

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

GlobeNewswire
·
10 Apr

UPM Raflatac becomes first labeling business to offer product footprints in customer quotes

PR Newswire
·
10 Apr

Esperion Therapeutics Price Target Maintained With a $5.00/Share by Needham

Dow Jones
·
08 Apr

Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?

Zacks
·
03 Apr

Esperion Appoints Robert E. Hoffman to Board of Directors

THOMSON REUTERS
·
01 Apr

Press Release: Esperion Appoints Robert E. Hoffman to Board of Directors

Dow Jones
·
01 Apr

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
24 Mar

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia

MT Newswires Live
·
20 Mar

Esperion aligns with U.S. FDA to initiate Phase 3 trials of bempedoic acid

TIPRANKS
·
20 Mar

Esperion Aligns With U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

THOMSON REUTERS
·
20 Mar

Esperion Therapeutics Inc - to Initiate Phase 3 Clinical Studies This Year

THOMSON REUTERS
·
20 Mar

Esperion Therapeutics Inc - Confirms Sufficient Data to Advance to Phase 3 Studies

THOMSON REUTERS
·
20 Mar

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

GlobeNewswire
·
20 Mar

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

Zacks
·
05 Mar

Q4 2024 Esperion Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
05 Mar

Esperion Therapeutics Reports Strong Revenue Growth in 2024

TIPRANKS
·
05 Mar

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Mar

Esperion Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
04 Mar